15.02.2013 Views

world cancer report - iarc

world cancer report - iarc

world cancer report - iarc

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Fig. 5.124 Pancreatic duct showing high-grade<br />

intraepithelial neoplasia.<br />

Fig. 5.125 Well-differentiated, mucus-secreting<br />

invasive ductal adenocarcinoma of the pancreas.<br />

Hereditary conditions<br />

Around 10% of cases of pancreatic <strong>cancer</strong><br />

exhibit some degree of familial risk, this<br />

fraction being the highest for any human<br />

organ site [6]. In this context, germline<br />

mutations have been identified in a number<br />

of oncogenes and tumour suppressors,<br />

including BRCA2, (predisposing to<br />

breast and pancreatic carcinoma) and<br />

p16 INK4 (predisposing to melanoma and<br />

pancreatic <strong>cancer</strong>) (Table 5.13). The<br />

STK11/LKB1 gene is mutated in Peutz-<br />

Jeghers syndrome patients, this group<br />

being predisposed to pancreatic <strong>cancer</strong><br />

[7]. Sufferers from hereditary pancreatitis<br />

experience attacks of acute pancreatitis<br />

from an early age and face a 40% risk of<br />

<strong>cancer</strong> by age 70. Most families appear to<br />

possess one of two mutations in the<br />

cationic trypsinogen gene (chromosome<br />

7q35) [8] which cause the production of a<br />

mutant protein. Consequently, associated<br />

enzymatic activity is not inactivated and is<br />

hypothesized to contribute to autodigestion<br />

of the pancreas and pancreatitis; <strong>cancer</strong><br />

may then be a consequence of the<br />

prolonged inflammatory microenvironment<br />

in the pancreas. Other conditions<br />

250 Human <strong>cancer</strong>s by organ site<br />

Gene Chromosome Mechanism of alteration % of <strong>cancer</strong>s<br />

Oncogenes<br />

KRAS 12p Point mutation > 90<br />

MYB, AKT2, AIB1 6q, 19q, 20q Amplification 1 10-20<br />

ERBB2 (HER/2-neu) 17q Overexpression 70<br />

Tumour suppressor genes<br />

p16 INK4A 9p Homozygous deletion 40<br />

Loss of heterozygosity 40<br />

and intragenic mutation<br />

Promoter hypermethylation 15<br />

p53 17p Loss of heterozygosity 50-70<br />

and intragenic mutation<br />

DPC4 18q Homozygous deletion 35<br />

Loss of heterozygosity 20<br />

and intragenic mutation<br />

BRCA2 13q Inherited intragenic 7<br />

mutation and loss<br />

of heterozygosity<br />

MKK4 17p Homozygous deletion, 4<br />

loss of heterozygosity<br />

and intragenic mutation<br />

LKB1/STK11 19p Loss of heterozygosity 5<br />

and intragenic mutation,<br />

homozygous deletion<br />

ALK5 and TGF βR2 9q, 3p Homozygous deletion 4<br />

DNA mismatch repair<br />

MSH2, MLH1, others 2p, 3p, others Unknown

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!